# Cell membrane-camouflaged inorganic nanoparticles for cancer therapy

**Authors:** Wanli Song, Pengfei Jia, Ting Zhang, Keke Dou, Lubin Liu, Yaping Ren, Fujun Liu, Junmiao Xue, Mohamed Sayed Hasanin, Hongzhao Qi, Qihui Zhou

PMC · DOI: 10.1186/s12951-022-01475-w · Journal of Nanobiotechnology · 2022-06-18

## TL;DR

This paper reviews how inorganic nanoparticles coated with cell membranes can improve cancer therapy by overcoming immune detection and enhancing drug delivery.

## Contribution

The paper provides a timely review of recent advances in cell membrane-camouflaged inorganic nanoparticles for cancer therapy.

## Key findings

- Cell membrane-coated nanoparticles inherit functional proteins and receptors for better tumor targeting.
- These nanoparticles show reduced immune detection and increased tumor accumulation.
- The review discusses both the potential and challenges of clinical translation for these nanoparticles.

## Abstract

Inorganic nanoparticles (INPs) have been paid great attention in the field of oncology in recent past years since they have enormous potential in drug delivery, gene delivery, photodynamic therapy (PDT), photothermal therapy (PTT), bio-imaging, driven motion, etc. To overcome the innate limitations of the conventional INPs, such as fast elimination by the immune system, low accumulation in tumor sites, and severe toxicity to the organism, great efforts have recently been made to modify naked INPs, facilitating their clinical application. Taking inspiration from nature, considerable researchers have exploited cell membrane-camouflaged INPs (CMCINPs) by coating various cell membranes onto INPs. CMCINPs naturally inherit the surface adhesive molecules, receptors, and functional proteins from the original cell membrane, making them versatile as the natural cells. In order to give a timely and representative review on this rapidly developing research subject, we highlighted recent advances in CMCINPs with superior unique merits of various INPs and natural cell membranes for cancer therapy applications. The opportunity and obstacles of CMCINPs for clinical translation were also discussed. The review is expected to assist researchers in better eliciting the effect of CMCINPs for the management of tumors and may catalyze breakthroughs in this area.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Hao1 (hydroxyacid oxidase 1, liver) [NCBI Gene 15112] {aka GOX, Gox1, Hao-1}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Selplg (selectin, platelet (p-selectin) ligand) [NCBI Gene 20345] {aka CD162, Psgl-1, Psgl1, Selp1, Selpl}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, Cd47 (CD47 antigen (Rh-related antigen, integrin-associated signal transducer)) [NCBI Gene 16423] {aka 9130415E20Rik, B430305P08Rik, IAP, Itgp}, Pmel (premelanosome protein) [NCBI Gene 20431] {aka D10H12S53E, D12S53Eh, Pmel17, Si, Silv, gp100}, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) [NCBI Gene 28] {aka A3GALNT, A3GALT1, GTA, GTB, NAGAT}
- **Diseases:** thrombosis (MESH:D013927), metastases (MESH:D009362), malignant ascites (MESH:D001201), inflammatory bowel disease (MESH:D015212), Melanoma cell (MESH:D008545), inflammation (MESH:D007249), pleural effusion (MESH:D010996), CCM (MESH:D020786), atherosclerotic thrombosis (MESH:D050197), colon tumors (MESH:D003110), HCM (MESH:D000092183), cytokine release syndrome (MESH:D000080424), non-melanoma skin cancer (MESH:D012878), death (MESH:D003643), CMCINPs (MESH:D015433), hypoxic tumor (MESH:D002534), toxicity (MESH:D064420), head and neck squamous cell carcinoma (MESH:D000077195), breast cancer (MESH:D001943), sepsis (MESH:D018805), Chinese Medicine (MESH:C562377), cancer metastasis (MESH:D009369), prostate cancer (MESH:D011471), Long-term chronic inflammation (MESH:D000088562), MRSA pneumonia (MESH:D011014), coronavirus (MESH:D018352)
- **Chemicals:** CpG (MESH:C015772), CuS (MESH:C017846), eosin (MESH:D004801), azide (MESH:D001386), cholesterol (MESH:D002784), graphene (MESH:D006108), sugars (MESH:D000073893), DiD (MESH:D017878), PS (MESH:D010758), lipid (MESH:D008055), Metal (MESH:D008670), Oxide (MESH:D010087), PLGA (MESH:D000077182), Au (MESH:D006046), MOF (MESH:C037042), MgCl2 (MESH:D015636), ROS (MESH:D017382), Sulfide (MESH:D013440), hematoxylin (MESH:D006416), FA (MESH:D005492), DOX (MESH:D004317), CaCl2 (MESH:D002122), phospholipid (MESH:D010743), PEG (MESH:D011092), glucose (MESH:D005947), Silica (MESH:D012822), manganese Dioxide (MESH:C016552), Fe (MESH:D007501), Rhodamine (MESH:D012235), IR780 (MESH:C548458), CPPO (MESH:C041020), carbohydrates (MESH:D002241), curcumin (MESH:D003474), Ce6 (MESH:C062985), gallium (MESH:D005708), AuNs (-), perfluorohexane (MESH:C078626), H2O (MESH:D014867), H2O2 (MESH:D006861), Calcium carbonate (MESH:D002119), mefuparib hydrochloride (MESH:C000626298), Fe3O4 (MESH:C000499), H&amp;E (MESH:D006371)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), UM-SCC-7 — Homo sapiens (Human), Oral cavity squamous cell carcinoma, Cancer cell line (CVCL_7776), HT1080 — Homo sapiens (Human), Fibrosarcoma, Cancer cell line (CVCL_0317), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), MDA-MB-435;CAL27 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0417), NHDF — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A3XU), KB Gold — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0372), B16 — Mus musculus (Mouse), Hybridoma (CVCL_U043), CAL27 — Homo sapiens (Human), Tongue adenosquamous carcinoma, Cancer cell line (CVCL_1107), RAW246.7 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_C237), RAW264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), MCF-7 Doxorubicin — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), SK-BR-3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), COS7 monkey — Macaca fascicularis (Crab-eating macaque), Spontaneously immortalized cell line (CVCL_3631), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), COS7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), H22 — Homo sapiens (Human), Peripheral primitive neuroectodermal tumor of bone, Cancer cell line (CVCL_1E32), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), HCT116;DU145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), HeLa cervical cancer — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_JX14), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9206402/full.md

## Figures

16 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9206402/full.md

## References

110 references — full list in the complete paper: https://tomesphere.com/paper/PMC9206402/full.md

---
Source: https://tomesphere.com/paper/PMC9206402